Table 2.
Fat cell volume and lipolysis in transwomen and transmen before initiated treatment (T00), after gonadal downregulation (T0), 3 months (T3) and 11 months (T11) after gender-affirming hormonal treatment was started
| Time | T00 | T0 | T3 | T11 | T00 vs T0 | T00 vs T3 | T00 vs T12 | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| n | Median (IQR) | n | Median (IQR) | n | Median (IQR) | n | Median (IQR) | p-value | p-value | p-value | |
| Transwomen | |||||||||||
| Fat cell volume (pL) | 15 | 387 (209–561) | 12 | 347 (271–534) | 11 | 340 (222–424) | 12 | 342 (284–517) | 0.80 | 0.47 | 0.74 |
| Basal lipolys (µmol glycerol/g TG/2 h) | 14 | 0.70 (0.57–0.88) | 12 | 0.64 (0.54–0.82) | 11 | 0.60 (0.43–0.98) | 12 | 0.88 (0.43–2.10) | 0.55 | 0.75 | 0.09 |
| Noradrenaline induced lipolysis (µmol glycerol/g TG/2 h) | 14 | 2.67 (1.23–3.64) | 12 | 2.98 (1.39–4.08) | 11 | 2.36 (1.42–4.13) | 12 | 3.00 (2.06–3.95) | 0.69 | 0.90 | 0.16 |
| Isoprenaline induced lipolysis (µmol glycerol/g TG/2 h) | 14 | 8.46 (3.51–9.40) | 12 | 5.79 (3.47–11.11) | 11 | 8.48 (4.08–9.87) | 12 | 7.16 (6.35–8.85) | 0.89 | 0.85 | 0.34 |
| Basal lipolysis (µmol glycerol/×107 cells/2 h) | 14 | 2.72 (1.27–3.55) | 12 | 2.03 (1.01–3.09) | 11 | 1.56 (0.96–2.27) | 12 | 3.21 (1.46–7.77) | 0.32 | 0.47 | 0.19 |
| Noradrenaline stimulated lipolysis (µmol glycerol/×107 cells/2 h) | 14 | 6.20 (4.79–13.10) | 12 | 8.90 (5.23–14.25) | 11 | 5.15 (4.50–13.38) | 12 | 9.26 (6.66–21.94) | 0.79 | 0.86 | 0.14 |
| Isoprenaline stimulated lipolysis (µmol glycerol/×107 cells/2 h) | 14 | 18.09 (15.24–32.89) | 12 | 19.26 (15.30–29.04) | 11 | 19.33 (14.67–29.84) | 12 | 22.38 (16.46–35.61) | 0.76 | 0.84 | 0.72 |
| Noradrenaline/Basal lipolysis (ratio) | 14 | 2.91 (1.85–4.41) | 12 | 3.57 (2.27–6.62) | 11 | 3.37 (2.70–5.68) | 12 | 3.47 (2.31–4.59) | 0.16 | 0.63 | 0.53 |
| Isoprenaline/Basal lipolysis (ratio) | 14 | 11.70 (4.82–14.56) | 12 | 10.22 (6.73–16.62) | 11 | 14.37 (5.66–18.62) | 12 | 7.68 (5.03–15.30) | 0.86 | 0.59 | 0.71 |
| Transmen | |||||||||||
| Fat cell volume (pL) | 14 | 430 (299–576) | 14 | 396 (308–519) | 14 | 545 (349–680) | 16 | 442 (300–609) | 0.76 | 0.09 | 0.87 |
| Basal lipolys (µmol glycerol/g TG/2 h) | 14 | 0.74 (0.34–1.02) | 14 | 0.94 (0.36–1.20) | 14 | 0.96 (0.52–1.30) | 16 | 1.05 (0.79–1.48) | 0.39 | 0.30 | 0.20 |
| Noradrenaline induced lipolysis (µmol glycerol/g TG/2 h) | 14 | 2.77 (1.54–3.72) | 14 | 3.81 (2.35–5.87) | 14 | 2.72 (1.57–3.44) | 16 | 2.71 (2.04–3.33) | 0.04 | 0.59 | 0.57 |
| Isoprenaline induced lipolysis (µmol glycerol/g TG/2 h) | 14 | 5.91 (5.14–7.38) | 14 | 7.48 (6.04–8.77) | 14 | 6.27 (5.43–7.95) | 16 | 5.77 (5.09–9.12) | 0.06 | 0.70 | 0.41 |
| Basal lipolysis (µmol glycerol/×107 cells/2 h) | 14 | 2.35 (1.26–4.55) | 14 | 2.94 (1.86–6.03) | 14 | 4.30 (2.02–7.54) | 16 | 3.09 (2.68–5.51) | 0.48 | 0.05 | 0.15 |
| Noradrenaline stimulated lipolysis (µmol glycerol/×107 cells/2 h) | 14 | 10.70 (4.68–16.60) | 14 | 14.52 (6.80–24.28) | 14 | 13.74 (6.66–22.35) | 16 | 9.69 (5.93–15.81) | 0.07 | 0.54 | 0.49 |
| Isoprenaline stimulated lipolysis (µmol glycerol/×107 cells/2 h) | 14 | 23.73 (17.68–27.88) | 14 | 31.12 (18.30–34.94) | 14 | 26.85 (25.15–36.64) | 16 | 23.19 (19.68–32.80) | 0.11 | 0.10 | 0.42 |
| Noradrenaline/Basal lipolysis (ratio) | 14 | 3.64 (2.38–5.45) | 14 | 4.00 (3.08–7.65) | 14 | 3.25 (1.54–4.97) | 16 | 2.45 (1.63–3.26) | 0.10 | 0.74 | 0.04 |
| Isoprenaline/Basal lipolysis (ratio) | 14 | 8.90 (5.91–13.01) | 14 | 9.06 (6.09–13.30) | 14 | 7.87 (4.97–13.35) | 16 | 6.19 (4.84–8.60) | 0.92 | 0.95 | 0.15 |
TG Triglycerides